Results 131 to 140 of about 2,901,268 (383)

Recognizing myofascial pelvic pain in the female patient with chronic pelvic pain. [PDF]

, 2012
Myofascial pelvic pain (MFPP) is a major component of chronic pelvic pain (CPP) and often is not properly identified by health care providers. The hallmark diagnostic indicator of MFPP is myofascial trigger points in the pelvic floor musculature that ...
Katzman, Wendy B, Pastore, Elizabeth A
core   +1 more source

Engineered Stable, Antibiotic‐Free, High‐Level Protein Expression in the Probiotic Chassis Escherichia coli Nissle 1917

Biotechnology and Bioengineering, EarlyView.
The probiotic E. coli Nissle 1917 was engineered to enable stable and antibiotic free protein expression platforms using native plasmids. Further modification aids in the production of high‐level protein expression for antimicrobial secretion whose activity is comparable to industry standard E. coli BL21.
Halimatun Sakdiah Zainuddin, Sanjeeva Kumar Murali, Thomas J. Mansell   +2 more
wiley   +1 more source

Chronic constipation: A critical review

Digestive and Liver Disease, 2013
Chronic constipation is a very common symptom that is rarely associated with life-threatening diseases, but has a substantial impact on patient quality of life and consumption of healthcare resources. Despite the large number of affected patients and the social relevance of the condition, no cost-effectiveness analysis has been made of any diagnostic ...
G. Basilisco, M. Coletta
openaire   +4 more sources

Current developments in pharmacological therapeutics for chronic constipation

Acta Pharmaceutica Sinica B, 2015
Chronic constipation is a common gastrointestinal disease severely affecting the patient׳s quality of life. The traditional treatment of constipation is the use of laxatives.
Chunhuan Jiang, Qinglong Xu, Xiaoan Wen, Hongbin Sun   +3 more
doaj   +1 more source

Relative Bioavailability, Food Effect, and Bioequivalence Studies to Assess a New Zanubrutinib 160‐mg Tablet: Results From 2 Phase 1 Studies in Healthy Volunteers

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Zanubrutinib is a next‐generation Bruton tyrosine kinase inhibitor approved for treating B‐cell malignancies. Two phase 1 studies evaluated a new 160‐mg zanubrutinib tablet versus 80‐mg capsules. In study BGB‐3111‐115 (n = 43), a randomized 3‐period crossover trial, relative bioavailability and food effects were assessed.
Bilal Tariq, Chester Lin, Vaibhav Mundra, Yang Gao, Dan Zhang, Ying C. Ou   +5 more
wiley   +1 more source

Chronic Constipation with Hemorrhoid at Single Man Because of Unhealthy Lifestyle [PDF]

, 2014
Chronic constipation is the inhibition of normal defecation habits. It is interpreted as rare, dry, and less consistency of stool. Constipation affects approximately 14.7% of the U.S.
Octaviani, I. (Intan)
core  

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective superagonist of the 5‐hydroxytryptamine 2C (5‐HT2C) receptor currently in development for the treatment of seizures that arise from developmental and epileptic encephalopathies. This phase 1, double‐blind, placebo‐controlled multiple ascending dose (MAD) study assessed the safety, tolerability, and ...
Jonathan Williams, Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R. Srinivas, Randall Kaye   +7 more
wiley   +1 more source

Epidemiology and Burden of Chronic Constipation

Canadian Journal of Gastroenterology, 2011
Chronic constipation is an important component of clinical gastroenterology practice worldwide. Based on the definition, either self-reported or using Rome criteria, chronic constipation can affect from 2% to 27% of the population.
Maria Ines Pinto Sanchez, Premysl Bercik
doaj   +1 more source

The relationship between quality of life (EORTC QLQ-C30) and survival in patients with gastro-oesopohageal cancer [PDF]

, 2008
It remains unclear whether any aspect of quality of life has a role in predicting survival in an unselected cohort of patients with gastro-oesophageal cancer. Therefore the aim of the present study was to examine the relationship between quality of life (
AB Crumley, AB Crumley, BH von Rahden, D C McMillan, DP Kotler, FM Fang, I Chau, J R Anderson, JM Blazeby, JM Blazeby, JR Siewert, LH Sobin, M McKernan, N Ando, N MacDonald, NK Aaronson, NK Aaronson, P O'Gorman, R C Stuart, SA Hundahl, T Conroy, W Hofstetter, W J Angerson, WD Dewys   +23 more
core   +2 more sources

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch, Wendy Weis, Felix Huth, Seshulatha Jamalapuram, Michelle Quinlan, Amarnath Bandaru, Suleyman Eralp Bellibas, Asmae Mirkou, Shruti Kapoor, Shefali Kakar   +9 more
wiley   +1 more source